Given that as many as 47% of patients with non–ST-segment elevation myocardial infarction (non-STEMI) belong to the grade “0” Thrombolysis in Myocardial Infarction (TIMI) flow category (when angiography is performed, which, in most patients, is within 6 hours of arrival in hospital),1 it may be premature to state that
Even allowing for some ambiguity in the wording of that statement, the role of percutaneous intervention (PCI) in patients with non-STEMI who have angiographic documentation of thrombotic occlusion within the 3-hour therapeutic time window, which is the one advocated for PCI treatment of acute myocardial infarction,3 can only be established by a randomized controlled trial. For such a trial to enroll sufficient numbers of patients, obstacles to early presentation2 will have to be eliminated, including the delay between arrival in hospital and team notification.1 Furthermore, when interpreting the results of such a trial, allowance will also have to be made for the fact that 60% to 65.5% of patients with non-STEMI have multivessel coronary artery disease,1,4 and that
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Acute Myocardial Infarction
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.